Abstract
Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.
| Original language | English |
|---|---|
| Pages (from-to) | 10-19 |
| Number of pages | 10 |
| Journal | Hepatology Research |
| Volume | 13 |
| Issue number | 1 |
| Publication status | Published - Dec 1998 |
Fingerprint
Keywords
- Bile acids
- Chronic hepatitis
- Dose-response relationship
- Liver disease
- Tauroursodeoxycholic acid
- Therapy
ASJC Scopus subject areas
- Gastroenterology
Cite this
Tauroursodeoxycholic acid for the treatment of chronic hepatitis : A multicentre dose-response study. / Crosignani, Andrea; Battezzati, Pier Maria; Cestari, Cristina; Stabilini, Roberto; Conte, Dario; Zappalà, Francesco; Floreani, Annarosa; Montalto, Giuseppe; Soresi, Maurizio; Notarbartolo, Alberto; Buscarini, Elisabetta; Buscarini, Luigi; Buongiorno, Giampiero; Manghisi, Onofrio Giuseppe; Podda, Mauro.
In: Hepatology Research, Vol. 13, No. 1, 12.1998, p. 10-19.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tauroursodeoxycholic acid for the treatment of chronic hepatitis
T2 - A multicentre dose-response study
AU - Crosignani, Andrea
AU - Battezzati, Pier Maria
AU - Cestari, Cristina
AU - Stabilini, Roberto
AU - Conte, Dario
AU - Zappalà, Francesco
AU - Floreani, Annarosa
AU - Montalto, Giuseppe
AU - Soresi, Maurizio
AU - Notarbartolo, Alberto
AU - Buscarini, Elisabetta
AU - Buscarini, Luigi
AU - Buongiorno, Giampiero
AU - Manghisi, Onofrio Giuseppe
AU - Podda, Mauro
PY - 1998/12
Y1 - 1998/12
N2 - Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.
AB - Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.
KW - Bile acids
KW - Chronic hepatitis
KW - Dose-response relationship
KW - Liver disease
KW - Tauroursodeoxycholic acid
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0032415992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032415992&partnerID=8YFLogxK
M3 - Article
VL - 13
SP - 10
EP - 19
JO - Hepatology Research
JF - Hepatology Research
SN - 1386-6346
IS - 1
ER -